Literature DB >> 12006335

Safety and efficacy of TNFalpha blockade in relapsing vasculitis.

A D Booth, H J Jefferson, W Ayliffe, P A Andrews, D R Jayne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12006335      PMCID： PMC1754125          DOI： 10.1136/ard.61.6.559

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  16 in total

Review 1.  New indications for biological therapies.

Authors:  Mariagrazia Catanoso; Nicolò Pipitone; Luca Magnani; Luigi Boiardi; Carlo Salvarani
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 2.  Wegener's granulomatosis: is biologic therapy useful?

Authors:  Pasha Sarraf; Jonathan Kay; Robert P Friday; Anthony M Reginato
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

3.  Novel strategy for the treatment of refractory vasculitis syndrome.

Authors:  Hidehiro Yamada
Journal:  Ann Vasc Dis       Date:  2013-02-15

Review 4.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Advances in the use of biologic agents for the treatment of systemic vasculitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Curr Opin Rheumatol       Date:  2009-01       Impact factor: 5.006

Review 6.  [Wegener's granulomatosis and microscopic polyangiitis].

Authors:  K de Groot; E Reinhold-Keller
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 7.  The utility of tumour necrosis factor blockade in orphan diseases.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 8.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Richard W Lee; David P D'Cruz
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Biologics for the treatment of autoimmune renal diseases.

Authors:  Stephen R Holdsworth; Poh-Yi Gan; A Richard Kitching
Journal:  Nat Rev Nephrol       Date:  2016-03-07       Impact factor: 28.314

Review 10.  TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis.

Authors:  Francisco Silva; Marcela Cisternas; Ulrich Specks
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.